Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Revenue (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Revenue for 15 consecutive years, with $202.1 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 11.12% to $202.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $761.4 million through Dec 2025, up 12.79% year-over-year, with the annual reading at $761.4 million for FY2025, 12.79% up from the prior year.
  • Revenue hit $202.1 million in Q4 2025 for Corcept Therapeutics, down from $207.6 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $207.6 million in Q3 2025 to a low of $79.4 million in Q1 2021.
  • Historically, Revenue has averaged $134.3 million across 5 years, with a median of $120.7 million in 2023.
  • Biggest five-year swings in Revenue: decreased 14.81% in 2021 and later soared 47.69% in 2024.
  • Year by year, Revenue stood at $98.8 million in 2021, then increased by 4.28% to $103.1 million in 2022, then skyrocketed by 31.39% to $135.4 million in 2023, then soared by 34.33% to $181.9 million in 2024, then rose by 11.12% to $202.1 million in 2025.
  • Business Quant data shows Revenue for CORT at $202.1 million in Q4 2025, $207.6 million in Q3 2025, and $194.4 million in Q2 2025.